Letter to the editor about: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.
作者信息
Ville Simon, Drapeau Leo, Paraire Jean, Maanaoui Mehdi, Frimat Marie
机构信息
Institut de Transplantation Urologie Néphrologie, CHU Nantes, Nantes, France.
Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.
出版信息
Kidney Int Rep. 2024 Mar 28;9(6):1932. doi: 10.1016/j.ekir.2024.02.1440. eCollection 2024 Jun.
Abstract
摘要
相似文献
1
Letter to the editor about: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.致编辑的信：关于“依库珠单抗优先”在移植后血栓性微血管病管理中的应用
Kidney Int Rep. 2024 Mar 28;9(6):1932. doi: 10.1016/j.ekir.2024.02.1440. eCollection 2024 Jun.
2
Response to Letter to the Editor From Ville S. et al. About: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.对Ville S.等人致编辑信的回复。主题：移植后血栓性微血管病管理中的“依库珠单抗优先”
Kidney Int Rep. 2024 Mar 27;9(6):1933-1934. doi: 10.1016/j.ekir.2024.03.029. eCollection 2024 Jun.
3
Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab.依库珠单抗成功逆转难治性移植后血栓性微血管病
Indian J Nephrol. 2024 Mar-Apr;34(2):191-194. doi: 10.4103/ijn.ijn_345_22. Epub 2023 Apr 4.
4
Eculizumab in Posttransplant TMA: Unproven Benefit: A Response to Maritati et al.: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.依库珠单抗治疗移植后血栓性微血管病：益处未得到证实：对马里蒂等人《移植后血栓性微血管病管理中的“先使用依库珠单抗”》的回应
Kidney Int Rep. 2024 Apr 8;9(6):1929. doi: 10.1016/j.ekir.2024.02.1442. eCollection 2024 Jun.
5
"Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.依库珠单抗优先用于移植后血栓性微血管病的管理
Kidney Int Rep. 2024 Jan 10;9(4):982-993. doi: 10.1016/j.ekir.2024.01.013. eCollection 2024 Apr.
6
Anti-neutrophil cytoplasmic antibody-associated vasculitis complicated by thrombotic microangiopathy with posterior reversible encephalopathy syndrome successfully treated with eculizumab: A case report.抗中性粒细胞胞质抗体相关性血管炎并发血栓性微血管病伴后部可逆性脑病综合征，成功使用依库珠单抗治疗：病例报告。
Mod Rheumatol Case Rep. 2022 Jun 24;6(2):254-259. doi: 10.1093/mrcr/rxac029.
7
A Caution Against the Use of C5b-9 Endothelial Assay to Support Eculizumab Therapy: A response to Maritati : "Eculizumab first" in the management of posttransplant thrombotic microangiopathy.关于使用C5b-9内皮细胞检测来支持依库珠单抗治疗的警示：对马里蒂的回应：移植后血栓性微血管病管理中的“先使用依库珠单抗”
Kidney Int Rep. 2024 Mar 1;9(5):1538. doi: 10.1016/j.ekir.2024.02.1434. eCollection 2024 May.
8
Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.依库珠单抗可改善因抗磷脂综合征复发导致的移植后血栓性微血管病，但不能预防慢性血管改变。
Am J Transplant. 2013 Aug;13(8):2179-85. doi: 10.1111/ajt.12319. Epub 2013 Jun 13.
9
Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case series and systematic review of the literature.贝伐珠单抗相关血栓性微血管病用依库珠单抗治疗：病例系列和文献系统评价。
Clin Nephrol. 2021 Jul;96(1):51-59. doi: 10.5414/CN110443.
10
Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy.同种异体干细胞移植后的血栓性微血管病：依库珠单抗治疗与常规治疗的比较。
Biol Blood Marrow Transplant. 2017 Dec;23(12):2172-2177. doi: 10.1016/j.bbmt.2017.08.019. Epub 2017 Aug 30.
本文引用的文献
1
"Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.依库珠单抗优先用于移植后血栓性微血管病的管理
Kidney Int Rep. 2024 Jan 10;9(4):982-993. doi: 10.1016/j.ekir.2024.01.013. eCollection 2024 Apr.
2
Thrombotic Microangiopathy in the Renal Allograft: Results of the TMA Banff Working Group Consensus on Pathologic Diagnostic Criteria.移植肾血栓性微血管病：Banff 工作组关于病理诊断标准的共识结果。
Transpl Int. 2023 Aug 23;36:11590. doi: 10.3389/ti.2023.11590. eCollection 2023.
3
Is the atypical hemolytic uremic syndrome risk polymorphism in Membrane Cofactor Protein MCPggaac relevant in kidney transplantation? A case report.非典型溶血尿毒症综合征风险多态性在 MCPggaac 膜辅助蛋白中与肾移植相关吗？ 1 例报告。
Pediatr Transplant. 2021 May;25(3):e13903. doi: 10.1111/petr.13903. Epub 2020 Nov 20.
4
Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.非典型和继发性溶血尿毒综合征具有独特的表现，且无共同的遗传风险因素。
Kidney Int. 2019 Jun;95(6):1443-1452. doi: 10.1016/j.kint.2019.01.023. Epub 2019 Mar 15.
5
Etiology and Outcomes of Thrombotic Microangiopathies.血栓性微血管病的病因和结局。
Clin J Am Soc Nephrol. 2019 Apr 5;14(4):557-566. doi: 10.2215/CJN.11470918. Epub 2019 Mar 12.
6
Successful Renal Transplantation of Deceased Donor Kidneys With 100% Glomerular Fibrin Thrombi and Acute Renal Failure Due to Disseminated Intravascular Coagulation.因弥散性血管内凝血导致100%肾小球纤维蛋白血栓形成及急性肾衰竭的已故供体肾脏的成功肾移植
Transplantation. 2017 Jun;101(6):1134-1138. doi: 10.1097/TP.0000000000001386.
Zotero 插件